OTUD7B stabilizes estrogen receptor α and promotes breast cancer cell proliferation.

OTUD7B stabilizes estrogen receptor α and promotes breast cancer cell proliferation.
复制标题

OTUD7B稳定雌激素受体α并促进乳腺癌细胞的增殖。

DOI:
10.1038/s41419-021-03785-7
复制
发表时间:
2021-05-25
影响因子:
9
通讯作者:
Wu G
Wu G
中科院分区:
生物学1区
文献类型:
--
作者:
Tang J;Wu Z;Tian Z;Chen W;Wu G

文献摘要

参考文献

被引文献

相似文献

乳腺癌是世界范围内女性最常见的恶性肿瘤。雌激素受体α(ERα)在约70%的乳腺癌病例中表达,并促进雌激素依赖性癌症进展。在本研究中,我们鉴定了卵巢肿瘤蛋白超家族A20亚群的去泛素化酶OTU结构域7 B(OTUD 7 B)为乳腺癌中ERα的真正去泛素化酶。乳腺癌组织中OTUD 7 B表达与ERα表达呈正相关,且与预后不良有关。OTUD 7 B可以以去泛素化活性依赖性方式与ER α相互作用、去泛素化和稳定ERα。OTUD 7 B缺失可降低乳腺癌细胞中ERα蛋白水平、ERα靶基因表达和雌激素反应元件活性。此外,OTUD 7 B耗竭显著降低ERα阳性乳腺癌细胞增殖和迁移。最后,ERα的过表达可以挽救OTUD 7 B缺失诱导的抑制作用,表明ERα状态对OTUD 7 B在乳腺癌发生中的功能至关重要。总之,我们的研究揭示了ERα阳性乳腺癌中ERα和OTUD 7 B之间有趣的翻译后机制。靶向OTUD 7 B-ER α复合物可能被证明是治疗ERα阳性乳腺癌患者的潜在方法。
Breast cancer is the most common malignancy in women worldwide. Estrogen receptor α (ERα) is expressed in ∼70% of breast cancer cases and promotes estrogen-dependent cancer progression. In the present study, we identified OTU domain-containing 7B (OTUD7B), a deubiquitylase belonging to A20 subgroup of ovarian tumor protein superfamily, as a bona fide deubiquitylase of ERα in breast cancer. OTUD7B expression was found to be positively correlated with ERα in breast cancer and associated with poor prognosis. OTUD7B could interact with, deubiquitylate, and stabilize ERα in a deubiquitylation activity-dependent manner. Depletion of OTUD7B decreased ERα protein level, the expression of ERα target genes, and the activity of estrogen response element in breast cancer cells. In addition, OTUD7B depletion significantly decreased ERα-positive breast cancer cell proliferation and migration. Finally, overexpression of ERα could rescue the suppressive effect induced by OTUD7B depletion, suggesting that the ERα status was essential to the function of OTUD7B in breast carcinogenesis. In conclusion, our study revealed an interesting post-translational mechanism between ERα and OTUD7B in ERα-positive breast cancer. Targeting the OTUD7B–ERα complex may prove to be a potential approach to treat patients with ERα-positive breast cancer.
DOI: 10.1186/bcr742
发表时间: 2004
期刊: Breast cancer research : BCR
影响因子: --
作者:
Shao W;Brown M
通讯作者: Brown M
DOI: 10.1128/mcb.06561-11
发表时间: 2012-05-01
影响因子: 5.3
作者:
Bhatt, Shweta;Xiao, Zhen;Katzenellenbogen, Benita S.
通讯作者: Katzenellenbogen, Benita S.
DOI: 10.1074/jbc.c000881200
发表时间: 2001-05-04
影响因子: 4.8
作者:
Hashizume, R;Fukuda, M;Ohta, T
通讯作者: Ohta, T
DOI: 10.1210/me.2005-0111
发表时间: 2005-12-01
影响因子: --
作者:
Fan, MY;Park, A;Nephew, KP
通讯作者: Nephew, KP
DOI: 10.1038/onc.2013.306
发表时间: 2014-06-26
期刊: ONCOGENE
影响因子: 8
作者:
Donley, C.;McClelland, K.;Robson, T.
通讯作者: Robson, T.